EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial

Alina N Saidi iD, Laura A M Konings, Carmen A W Dietvorst, Vivian D de Jong, Willem Pieter Brouwer, Aart-Jan van der Lelij, Marco Alings, Martien van Wenum, Simone P Rauh, Weiwei Xu, Manuel Castro Cabezas

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.70071 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Alina N Saidi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Naltrexone, Obesity, Overweight, Liver Cirrhosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is prevalent among individuals with overweight or obesity and type 2 diabetes (T2DM), increasing the risk for liver‐related and cardiovascular complications. Lifestyle changes to reduce body weight are the primary intervention to decrease the risk of MASLD and liver fibrosis. This study aimed to evaluate the impact of a pharmacological intervention with naltrexone/bupropion (NB) on hepatic steatosis and fibrosis risk in patients with T2DM using non‐invasive tests. Materials and Methods In this post hoc analysis of a 56‐week, randomized, double‐blind, placebo‐controlled trial 505 adults with T2DM and overweight or obesity were randomized to either NB or placebo (2:1), both combined with structured lifestyle counselling. Hepatic outcomes were measured using the Hepatic Steatosis Index (HSI), Metabolic Dysfunction‐Associated Fibrosis‐5 (MAF‐5) and Fibrosis‐4 (FIB‐4) indices. Changes in liver‐related indices were analysed by treatment arm and weight loss strata (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneObesityOverweightLiver CirrhosisDiabetes Mellitus, Type 2BupropionFatty LiverHumansMaleFemaleMiddle AgedDouble-Blind MethodWeight LossAdultTreatment OutcomeNon-alcoholic Fatty Liver DiseaseDrug Therapy, CombinationAnti-Obesity Agents

Stichwörter der Autor:innen

MASHMASLDliver fibrosisliver steatosisnaltrexone‐bupropionweight loss

Substanzen

NaltrexoneBupropionAnti-Obesity Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Julius Center for Health Science and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Julius Clinical, Zeist, The Netherlands.
  • Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Cardiology, Amphia Hospital, Breda, The Netherlands.

ORCID-Profile: Alina N Saidi

Zitieren

APA

Saidi, A. N., Konings, L. A. M., Dietvorst, C. A. W., de Jong, V. D., Brouwer, W. P., van der Lelij, A. J., Alings, M., van Wenum, M., Rauh, S. P., Xu, W., & Castro Cabezas, M. (2025). Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70071

Vancouver

Saidi AN, Konings LAM, Dietvorst CAW, de Jong VD, Brouwer WP, van der Lelij AJ, et al. Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70071

BibTeX
@article{Saidi2025,
  author = {Saidi, Alina N and Konings, Laura A M and Dietvorst, Carmen A W and de Jong, Vivian D and Brouwer, Willem Pieter and van der Lelij, Aart-Jan and Alings, Marco and van Wenum, Martien and Rauh, Simone P and Xu, Weiwei and Castro Cabezas, Manuel},
  title = {Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.70071}
}
Kostenlos starten →